Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

April

6

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

15

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

ROCKAWAY, N.J.–(BUSINESS WIRE)–Mar. 15, 2021– Amid the vaccine rollout, 97,309 new cases of COVID-19...

24

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

electroCore and the Hospital Clínico Universitario de Valencia have completed patient enrollment in SAVIOR-1 study ROCKAWAY,...

12

electroCore Announces Third Quarter Financial Results

Revenue growth of 44% over the second quarter of 2020 and 58% over the third quarter of 2019...

13

electroCore Provides Business Update and Select Financial Guidance

Third quarter 2020 Revenue expected to exceed $1 million, representing an increase of greater than 35% sequentially...

24

electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV

Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus...

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

Reimbursement for gammaCore™ in England BASKING RIDGE, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

13

electroCore Announces Second Quarter Financial Results

Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected...

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Initial distribution to hospitals and patients expected to begin on July 31st BASKING RIDGE,...

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

Paper supports use of nVNS as a front-line therapy for acute and preventative treatment...

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

Intended use allows gammaCore Sapphire CV use at home or in a healthcare setting...

Recent developments

News

April

6

electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

March

15

Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms

February

24

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

November

12

electroCore Announces Third Quarter Financial Results

October

13

electroCore Provides Business Update and Select Financial Guidance

September

24

electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire™ CV

August

24

electroCore, Inc. Announces Publication of a Voluntary ex-ante Transparency Tender Notice Award by NHS England to Fund Continued Use of gammaCore™ in England

August

13

electroCore Announces Second Quarter Financial Results

July

30

electroCore Provides Update on Availability of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients

July

28

electroCore Announces Non-Invasive Vagus Nerve Stimulation Clinical Update Publication in Cephalalgia

July

13

electroCore Announces FDA Emergency Use Authorization for use of gammaCore Sapphire™ CV for the Acute Treatment of Asthma Exacerbations in Known or Suspected COVID-19 Patients